Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced a poster presentation at ISPOR 2026 that will feature findings from a retrospective cohort study analyzing U.S. claims data from adults with fibromyalgia between April 2021 and April 2024. The presentation will provide real-world insights into fibromyalgia treatment, following the FDA approval of TONMYA in August 2025 and its U.S. commercial launch in November 2025.
TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg) is the first new treatment for fibromyalgia in more than 15 years, addressing a significant unmet medical need. The company’s fully integrated commercial-stage biotechnology focus includes central nervous system (CNS) and immunology treatments. Tonix’s CNS commercial infrastructure supports its marketed products, including acute migraine treatments Zembrace SymTouch and Tosymra.
The real-world data being presented is crucial for understanding how fibromyalgia is managed in clinical practice, especially with the introduction of a novel therapy. Fibromyalgia affects millions of Americans, and treatment options have been limited. The study’s findings could inform healthcare providers and payers about current treatment patterns and potential shifts with the availability of TONMYA.
Beyond fibromyalgia, Tonix is exploring the potential of TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder. The company’s CNS pipeline also includes TNX-2900, which is Phase 2 ready for Prader-Willi syndrome, a rare disease. In immunology, Tonix is advancing monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for preventing kidney transplant rejection.
The presentation at ISPOR 2026 underscores Tonix’s commitment to generating evidence on real-world treatment outcomes. As the healthcare landscape evolves, such data can influence clinical guidelines, reimbursement decisions, and patient access to innovative therapies. Investors and stakeholders can follow updates on TNXP in the company’s newsroom at https://ibn.fm/TNXP.
For more details on the press release, visit https://ibn.fm/A3668. Tonix Pharmaceuticals’ product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
